Cargando…

Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction

Leukocytosis is a common finding in patients with ST elevation myocardial infarction (STEMI) and portends a poor prognosis. Interleukin 1-β regulates leukopoiesis and pre-clinical studies suggest that anakinra (recombinant human interleukin-1 [IL-1] receptor antagonist) suppresses leukocytosis in my...

Descripción completa

Detalles Bibliográficos
Autores principales: Del Buono, Marco Giuseppe, Damonte, Juan Ignacio, Trankle, Cory R., Kadariya, Dinesh, Carbone, Salvatore, Thomas, Georgia, Turlington, Jeremy, Markley, Roshanak, Canada, Justin M., Biondi‐Zoccai, Giuseppe G., Kontos, Michael C., Van Tassell, Benjamin W., Abbate, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786840/
https://www.ncbi.nlm.nih.gov/pubmed/35075216
http://dx.doi.org/10.1038/s41598-022-05374-w
_version_ 1784639206426935296
author Del Buono, Marco Giuseppe
Damonte, Juan Ignacio
Trankle, Cory R.
Kadariya, Dinesh
Carbone, Salvatore
Thomas, Georgia
Turlington, Jeremy
Markley, Roshanak
Canada, Justin M.
Biondi‐Zoccai, Giuseppe G.
Kontos, Michael C.
Van Tassell, Benjamin W.
Abbate, Antonio
author_facet Del Buono, Marco Giuseppe
Damonte, Juan Ignacio
Trankle, Cory R.
Kadariya, Dinesh
Carbone, Salvatore
Thomas, Georgia
Turlington, Jeremy
Markley, Roshanak
Canada, Justin M.
Biondi‐Zoccai, Giuseppe G.
Kontos, Michael C.
Van Tassell, Benjamin W.
Abbate, Antonio
author_sort Del Buono, Marco Giuseppe
collection PubMed
description Leukocytosis is a common finding in patients with ST elevation myocardial infarction (STEMI) and portends a poor prognosis. Interleukin 1-β regulates leukopoiesis and pre-clinical studies suggest that anakinra (recombinant human interleukin-1 [IL-1] receptor antagonist) suppresses leukocytosis in myocardial infarction. However, the effect of IL-1 blockade with anakinra on leukocyte count in patients with STEMI is unknown. We reviewed the white blood cell (WBC) and differential count of 99 patients enrolled in a clinical trial of anakinra (n = 64) versus placebo (n = 35) for 14 days after STEMI. A complete blood cell count with differential count were obtained at admission, and after 72 h, 14 days and 3 months. After 72 h from treatment, anakinra compared to placebo led to a statistically significant greater percent reduction in total WBC count (− 35% [− 48 to − 24] vs. − 21% [− 34 to − 10], P = 0.008), absolute neutrophil count (− 48% [− 60 to − 22] vs. − 27% [− 46 to − 5], P = 0.004) and to an increase in absolute eosinophil count (+ 50% [0 to + 100] vs. 0% [− 50 to + 62], P = 0.022). These changes persisted while on treatment at 14 days and were no longer apparent at 3 months after treatment discontinuation. We found that in patients with STEMI IL-1 blockade with anakinra accelerates resolution of leukocytosis and neutrophilia. This modulation may represent one of the mechanisms by which IL-1 blockade improves clinical outcomes.
format Online
Article
Text
id pubmed-8786840
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-87868402022-01-25 Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction Del Buono, Marco Giuseppe Damonte, Juan Ignacio Trankle, Cory R. Kadariya, Dinesh Carbone, Salvatore Thomas, Georgia Turlington, Jeremy Markley, Roshanak Canada, Justin M. Biondi‐Zoccai, Giuseppe G. Kontos, Michael C. Van Tassell, Benjamin W. Abbate, Antonio Sci Rep Article Leukocytosis is a common finding in patients with ST elevation myocardial infarction (STEMI) and portends a poor prognosis. Interleukin 1-β regulates leukopoiesis and pre-clinical studies suggest that anakinra (recombinant human interleukin-1 [IL-1] receptor antagonist) suppresses leukocytosis in myocardial infarction. However, the effect of IL-1 blockade with anakinra on leukocyte count in patients with STEMI is unknown. We reviewed the white blood cell (WBC) and differential count of 99 patients enrolled in a clinical trial of anakinra (n = 64) versus placebo (n = 35) for 14 days after STEMI. A complete blood cell count with differential count were obtained at admission, and after 72 h, 14 days and 3 months. After 72 h from treatment, anakinra compared to placebo led to a statistically significant greater percent reduction in total WBC count (− 35% [− 48 to − 24] vs. − 21% [− 34 to − 10], P = 0.008), absolute neutrophil count (− 48% [− 60 to − 22] vs. − 27% [− 46 to − 5], P = 0.004) and to an increase in absolute eosinophil count (+ 50% [0 to + 100] vs. 0% [− 50 to + 62], P = 0.022). These changes persisted while on treatment at 14 days and were no longer apparent at 3 months after treatment discontinuation. We found that in patients with STEMI IL-1 blockade with anakinra accelerates resolution of leukocytosis and neutrophilia. This modulation may represent one of the mechanisms by which IL-1 blockade improves clinical outcomes. Nature Publishing Group UK 2022-01-24 /pmc/articles/PMC8786840/ /pubmed/35075216 http://dx.doi.org/10.1038/s41598-022-05374-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Del Buono, Marco Giuseppe
Damonte, Juan Ignacio
Trankle, Cory R.
Kadariya, Dinesh
Carbone, Salvatore
Thomas, Georgia
Turlington, Jeremy
Markley, Roshanak
Canada, Justin M.
Biondi‐Zoccai, Giuseppe G.
Kontos, Michael C.
Van Tassell, Benjamin W.
Abbate, Antonio
Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction
title Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction
title_full Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction
title_fullStr Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction
title_full_unstemmed Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction
title_short Effect of interleukin-1 blockade with anakinra on leukocyte count in patients with ST-segment elevation acute myocardial infarction
title_sort effect of interleukin-1 blockade with anakinra on leukocyte count in patients with st-segment elevation acute myocardial infarction
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8786840/
https://www.ncbi.nlm.nih.gov/pubmed/35075216
http://dx.doi.org/10.1038/s41598-022-05374-w
work_keys_str_mv AT delbuonomarcogiuseppe effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction
AT damontejuanignacio effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction
AT tranklecoryr effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction
AT kadariyadinesh effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction
AT carbonesalvatore effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction
AT thomasgeorgia effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction
AT turlingtonjeremy effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction
AT markleyroshanak effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction
AT canadajustinm effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction
AT biondizoccaigiuseppeg effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction
AT kontosmichaelc effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction
AT vantassellbenjaminw effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction
AT abbateantonio effectofinterleukin1blockadewithanakinraonleukocytecountinpatientswithstsegmentelevationacutemyocardialinfarction